Aberdeen Group
FULC icon

Aberdeen Group’s Fulcrum Therapeutics FULC Stock Holding History

Aberdeen Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17M Buy
2,211,953
+957,926
+76% +$8.89M 0.03% 468
2025
Q4 		$14.2M Buy
1,254,027
+1,116,066
+809% +$11.4M 0.02% 534
2025
Q3 		$1.27M Buy
137,961
+79,265
+135% +$573K ﹤0.01% 819
2025
Q2 		$404K Buy
+58,696
New +$314K ﹤0.01% 901
2024
Q3 		– Sell
-256,888
Closed -$1.59M – 936
2024
Q2 		$1.59M Hold
256,888
– – ﹤0.01% 777
2024
Q1 		$2.43M Hold
256,888
– – ﹤0.01% 755
2023
Q4 		$1.73M Buy
+256,888
New +$1.14M ﹤0.01% 785

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Aberdeen Group's FULC Position: Q1 2026 in Review

Aberdeen Group increased its Fulcrum Therapeutics (FULC) stake by 76% in Q1 2026, buying an estimated $8.89M and bringing the position to 2,211,953 shares worth $17M. The position accounts for 0.03% of the portfolio, ranked #468.

Aberdeen Group first reported a position in FULC in Q4 2023 and has held it in 7 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Aberdeen Group held 2,211,953 shares of Fulcrum Therapeutics worth $17M as of Q1 2026.
  • Aberdeen Group bought 957,926 Fulcrum Therapeutics shares in Q1 2026, an estimated $8.89M.
  • Fulcrum Therapeutics made up 0.03% of Aberdeen Group's portfolio in Q1 2026, its #468 holding.
  • Aberdeen Group first reported a position in Fulcrum Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.